Tag: Obesity

According to findings from the SURMOUNT clinical trials, individuals who discontinued tirzepatide (the active ingredient in Mounjaro) regained a significant portion of their lost weight, highlighting the need for long-term treatment. A key question for many patients considering this medication is **how long should someone be on Mounjaro for weight loss?**

According to a 2025 study, GLP-1 medications like semaglutide were found to be effective for weight loss in people with inflammatory bowel disease (IBD), with a safety profile comparable to those without IBD. Yet, the question remains: Can you take weight loss injections with Crohn's disease, given its potential for severe gastrointestinal side effects?.

Clinical data indicates that individuals taking semaglutide, the active ingredient in Ozempic, lost an average of 5.9% of their body weight in three months during one study. This helps set realistic expectations for how much weight can be lost in 3 months on Ozempic, though individual results can vary significantly.

While most Mounjaro clinical trials excluded patients with prior bariatric procedures, medical professionals are increasingly considering its use for managing weight regain or insufficient weight loss after surgery. For those asking, 'Can I take Mounjaro if I've had a gastric bypass?', the answer is often yes, but with careful medical supervision and a thorough understanding of the unique risks and benefits.

Over 80% of individuals with obesity experience insulin resistance, prompting many to question: **Will semaglutide work if I have insulin resistance?** Clinical trials and real-world studies confirm that semaglutide, through its powerful effects on weight management and blood sugar control, can significantly improve insulin sensitivity.

According to the NIH LiverTox database, tirzepatide (Mounjaro) is an exceedingly rare cause of clinically apparent acute liver injury. While uncommon, patients and clinicians still question if **can mounjaro cause liver damage** and what precautions are necessary. This guide explores the potential for liver-related side effects and the drug's overall impact on hepatic health.

Despite both being used for weight management, Alli (orlistat) and Ozempic (semaglutide) operate through fundamentally different pharmacological pathways and have distinct uses, making them largely incomparable in terms of efficacy and mechanism. A clear understanding of these differences is critical for anyone considering their options for weight loss.

In November 2023, the U.S. Food and Drug Administration (FDA) officially approved tirzepatide (marketed as Zepbound) for chronic weight management, directly answering the question: **is tirzepatide approved for long-term use?** for this specific purpose. This approval was based on robust clinical trial data showing sustained efficacy over extended periods, highlighting a significant shift towards considering obesity and related conditions as chronic diseases requiring long-term treatment.

As of October 2024, Eli Lilly is the most valuable drug company in the world with a market capitalization of $842 billion. This article explores the question: What is Eli Lilly known for, from its foundational role in medicine to its current market dominance?

According to multiple clinical studies and meta-analyses, semaglutide significantly reduces total cholesterol and triglycerides, while modestly increasing high-density lipoprotein cholesterol ($HDL-C$). This growing body of evidence confirms that semaglutide affects the lipid panel, contributing to important cardiovascular benefits beyond just weight loss and glycemic control.